Literature DB >> 7021435

Cyclosporin A for the treatment of systemic lupus erythematosus.

D A Isenberg, M L Snaith, W J Morrow, A A Al-Khader, S L Cohen, C Fisher, J Mowbray.   

Abstract

Cyclosporin A (CyA) was given to five patients with active systemic lupus erythematosus (SLE) at a dose of 10 mg/kg/day orally. No patient was able to take the drug for longer than seven weeks because of side effects including nephrotoxicity. Angio-oedema was noted in three patients and serum C1 esterase inhibitor levels were shown to be depressed in four out of five patients whilst taking CyA. Two patients did experience an improvement in their arthralgia but given the side effects induced we cannot, at present, recommend CyA for the treatment of SLE.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7021435     DOI: 10.1016/0192-0561(81)90007-2

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  10 in total

Review 1.  Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge.

Authors:  Y Ioannou; D A Isenberg
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 2.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

3.  Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.

Authors:  K Yamamoto; A Mori; T Nakahama; M Ito; H Okudaira; T Miyamoto
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

Review 4.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

5.  Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.

Authors:  A A Drosos; F N Skopouli; J S Costopoulos; C S Papadimitriou; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

Review 6.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 7.  Cyclosporine: immunology, toxicity and pharmacology in experimental animals.

Authors:  A W Thomson; P H Whiting; J G Simpson
Journal:  Agents Actions       Date:  1984-10

Review 8.  P-glycoprotein and drug resistance in systemic autoimmune diseases.

Authors:  Andrea Picchianti-Diamanti; Maria Manuela Rosado; Marco Scarsella; Bruno Laganà; Raffaele D'Amelio
Journal:  Int J Mol Sci       Date:  2014-03-20       Impact factor: 5.923

Review 9.  TAC-TIC use of tacrolimus-based regimens in lupus nephritis.

Authors:  Tineke Kraaij; Obbo W Bredewold; Stella Trompet; Tom W J Huizinga; Ton J Rabelink; Anton J M de Craen; Y K Onno Teng
Journal:  Lupus Sci Med       Date:  2016-12-29

Review 10.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.